利奈唑胺联合HRZE抗结核方案治疗肺结核的疗效及对T淋巴细胞亚群水平的影响

doi:10.3760/cma.j.issn.1007-1245.2023.10.004

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (10): 1348-1352.DOI: 10.3760/cma.j.issn.1007-1245.2023.10.004

利奈唑胺联合HRZE抗结核方案治疗肺结核的疗效及对T淋巴细胞亚群水平的影响

石俊霞¹ 王心宇¹ 史田田¹ 王德翠²

¹滨州市中心医院滨州市结核病防治院药剂科，滨州　251700；²滨州市中心医院滨州市结核病防治院结核科一病区，滨州　251700

收稿日期:2023-01-13 出版日期:2023-05-15 发布日期:2023-05-16
通讯作者: 石俊霞，Email：Shi69967@163.com
基金资助:
山东省医药卫生科技发展计划项目（2019WS010）

Linezolid combined with HRZE antituberculosis regimen in treatment of pulmonary tuberculosis and its effect T lymphocyte subsets

Shi Junxia¹, Wang Xinyu¹, Shi Tiantian¹, Wang Decui²

¹Pharmacy Department, Binzhou Central Hospital, Binzhou Antituberculosis Hospital, Binzhou 251700, China; ²First Division, Tuberculosis Department, Binzhou Central Hospital, Binzhou Antituberculosis Hospital, Binzhou 251700, China

Received:2023-01-13 Online:2023-05-15 Published:2023-05-16
Contact: Shi Junxia, Email: Shi69967@163.com
Supported by:
Project of Developmental Plan of Medical and Health Science and Technology in Shandong (2019WS010)

摘要/Abstract

摘要：

目的　探讨利奈唑胺联合HRZE（异烟肼、利福平、吡嗪酰胺、乙胺丁醇）抗结核方案治疗肺结核患者的价值。方法　选取滨州市中心医院2021年5月至2022年11月收治的肺结核患者80例进行随机对照试验，随机数字表法将其分为研究组和对照组，各40例。研究组男22例、女18例，年龄30～65（45.68±4.15）岁。对照组男24例、女16例，年龄32～63（45.50±4.20）岁。研究组采用利奈唑胺联合HRZE抗结核方案治疗，对照组采用HRZE抗结核方案治疗。对比两组治疗前后T淋巴细胞亚群水平、临床指标（病灶吸收缩小时间、空洞闭合时间、痰培养转阴时间）、实验室指标［干扰素-γ（INF-γ）、白细胞介素-6（IL-6）、转化生长因子-β（TGF-β）］、临床疗效及不良反应。采用χ²检验和t检验。结果　治疗前，两组CD3^＋、CD4^＋、CD4^＋/CD8^＋对比，差异均无统计学意义（均P>0.05）；治疗后，研究组CD3^＋、CD4^＋、CD4^＋/CD8^＋为（55.16±5.46）%、（39.64±4.55）%、（1.87±0.40），均高于对照组的（50.41±5.11）%、（33.26±4.12）%、（1.55±0.39）（均P<0.05）。研究组病灶吸收缩小时间、空洞闭合时间、痰培养转阴时间为（42.55±5.68）d、（89.65±6.38）d、（45.22±5.41）d，均短于对照组的（56.36±7.10）d、（116.20±8.12）d、（52.02±5.69）d（均P<0.05）。治疗前，两组INF-γ、IL-6、TGF-β水平对比，差异均无统计学意义（均P>0.05）；治疗后，研究组INF-γ水平高于对照组［（40.13±5.22）ng/L比（31.05±4.68）ng/L］，IL-6、TGF-β水平均低于对照组［（25.16±2.24）ng/L比（33.20±2.66）ng/L、（33.16±4.14）μg/L比（45.25±5.31）μg/L］（均P<0.05）。研究组总有效率高于对照组［95.00%（38/40）比77.50%（31/40），P<0.05］。两组不良反应发生率对比，差异无统计学意义（P>0.05）。结论　利奈唑胺联合HRZE抗结核方案治疗肺结核具有较好的效果及安全性，能够改善患者T淋巴细胞亚群水平，降低炎性水平，优化临床指标，临床价值较高。

关键词:

肺结核, 利奈唑胺, HRZE抗结核方案, T淋巴细胞亚群

Abstract:

Objective　To investigate the value of linezolid combined with HRZE (isoniazide, rifampicin, pyrazinamide, and ethambutol) antituberculosis regimen in the treatment of pulmonary tuberculosis. Methods　Eighty patients with pulmonary tuberculosis admitted to Binzhou Central Hospital from May 2021 to November 2022 were selected for the randomized controlled trial. They were divided into a study group and a control group by the random number table method, with 40 cases in each group. There were 22 males and 18 females in the study group; they were 30-65 (45.68±4.15) years old. There were 24 males and 16 females in the control group; they were 32-63 (45.50±4.20) years old. The study group were treated with linezolid and HRZE antituberculosis regimen, and the control group with HRZE antituberculosis regimen. The T lymphocyte subsets, clinical indicators (absorption reduction time, cavity closure time, and sputum culture negative time), and laboratory indicators [interferon-γ, interleukin-6 (IL-6), and transforming growth factor-β (TGF-β)] before and after the treatment, clinical efficacies, and adverse reactions were compared between the two groups. χ² and t tests were applied. Results　Before the treatment, there were no statistical differences in CD3⁺, CD4⁺, and CD4⁺/CD8⁺ between the two groups (all P>0.05); after the treatment, the CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the study group were higher than those in the control group [(55.16±5.46)% vs. (50.41±5.11)%, (39.64±4.55)% vs. (33.26±4.12)%, and (1.87±0.40) vs. (1.55±0.39); all P<0.05]. The absorption reduction time, cavity closure time, and sputum culture negative time in the study group were shorter than those in the control group [(42.55±5.68) d vs. (56.36±7.10) d, (89.65±6.38) d vs. (116.20±8.12) d, and (45.22±5.41) d vs. (52.02±5.69) d; all P<0.05]. Before the treatment, there were no statistical differences in the levels of interferon-γ, IL-6, and TGF-β between the two groups (all P>0.05); after the treatment, the INF-γ level was higher and the levels of IL-6 and TGF-β were lower in the study group than in the control group [(40.13±5.22) ng/L vs. (31.05±4.68) ng/L, (25.16±2.24) ng/L vs. (33.20±2.66) ng/L, and (33.16±4.14) μg/L vs. (45.25±5.31) μg/L; all P<0.05]. The total effective rate of the study group was higher than that of the control group [95.00% (38/40) vs. 77.50% (31/40); P<0.05]. There was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion　Linezolid combined with HRZE antituberculosis regimen in the treatment of pulmonary tuberculosis is effective and safe and can improve the patients' levels of T lymphocyte subsets, reduce inflammation, and optimize clinical indicators, so it has high clinical value.

Key words:

Pulmonary tuberculosis, Linezolid, HRZE antituberculosis regimen, T-lymphocyte subsets

石俊霞王心宇史田田王德翠.

利奈唑胺联合HRZE抗结核方案治疗肺结核的疗效及对T淋巴细胞亚群水平的影响 [J]. 国际医药卫生导报, 2023, 29(10): 1348-1352.

Shi Junxia, Wang Xinyu, Shi Tiantian, Wang Decui.

Linezolid combined with HRZE antituberculosis regimen in treatment of pulmonary tuberculosis and its effect T lymphocyte subsets [J]. International Medicine and Health Guidance News, 2023, 29(10): 1348-1352.

参考文献

[1] 杜光明,熊暁琪,杨忠诚. 注射用重组人白细胞介素-2联合2HRZE/4HR方案对肺结核患者病灶吸收率和免疫功能的影响[J]. 临床和实验医学杂志,2022,21(8):811-814. DOI:10.3969/j.issn.1671-4695.2022.08.008.
[2] 方刚,顾小燕,尹小芳. 母牛分枝杆菌菌苗辅助抗结核方案治疗肺结核对患者免疫功能及疾病转归的影响[J]. 中国临床研究,2020,33(4):501-504. DOI: 10.13429/j.cnki.cjcr.2020.04.017.
[3] 罗兰,何国庆. 内消瘰疬丸联合2HRZE/4HR方案治疗肺结核的效果观察及对细胞因子和免疫功能的影响[J]. 空军医学杂志,2020,36(1):41-44. DOI: 10.3969/j.issn.2095- 3402. 2020.01.013.
[4] 冯静,李姗,徐金平. 疗肺宁片联合2HRZE/4HR方案治疗活动性肺结核的疗效观察及其对PCT、IL-10、TNF-α水平的影响[J]. 药物评价研究,2021,44(3):550-555. DOI:10.7501/j.issn.1674-6376.2021.03.014.
[5] 冯华,缪勇,邓珊,等. 宣肺行气活血方联合2HRZE/4HR方案治疗结核性胸膜炎对患者血清Th1/Th2动态平衡的影响[J]. 四川中医,2021,39(4):71-74.
[6] 王全军,高嫦娥,蒋洁. 抗结核用药方案联合抗病毒用药方案治疗肺结核合并e抗原阳性慢性乙肝病毒携带患者的临床效果[J]. 贵州医药,2020,44(10):1550-1551. DOI:10.3969/j.issn.1000-744X.2020.10.014.
[7] 张培元. 肺结核诊断和治疗指南[J]. 中华结核和呼吸杂志,2001,24(2):70-74. DOI:10.3760/j:issn:1001-0939. 2001.02.002.
[8] Wu W, Li L, Duan S, et al. Clinical effectiveness and reliability of linezolid in the treatment of pulmonary tuberculosis complicated with severe pneumonia: a meta-analysis [J]. Am J Transl Res, 2022, 14(11): 7622-7631.
[9] An H, Liu X, Wang T, et al. Endobronchial valve treatment of tuberculous cavities in patients with multidrug-resistant pulmonary tuberculosis: a randomized clinical study [J]. Pathogens, 2022, 11(8):899. DOI: 10.3390/pathogens11080899.
[10] 刁利霞,吴宇平,邓俊亮. 胸腺五肽联合常规抗结核化疗方案在复治涂阳肺结核治疗中的应用[J]. 海南医学,2021,32(7):892-894. DOI:10.3969/j.issn.1003-6350. 2021.07.020.
[11] 潘蕾,毛敏杰,黄晓庆,等. 利奈唑胺治疗肺结核合并重症肺炎的疗效及对患者免疫因子和预后的影响[J]. 中华全科医学,2019,17(1):47-51. DOI:10.16766/j.cnki.issn.1674-4152.000596.
[12] Mota F, Jadhav R, Ruiz-Bedoya CA, et al. Radiosynthesis and biodistribution of 18F-linezolid in Mycobacterium tuberculosis-infected mice using positron emission tomography [J]. ACS Infect Dis, 2020, 6(5):916-921. doi: 10.1021/acsinfecdis.9b00473.
[13] Lee JK, Lee JY, Kim DK, et al. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial [J]. Lancet Infect Dis, 2019, 19(1):46-55. DOI: 10.1016/S1473-3099(18)30480-8.
[14] 高岭,任鹏飞,常娅莉,等. 利奈唑胺/环丝氨酸对耐多药肺结核患者细胞免疫及体液免疫的影响及安全性评价[J]. 中国免疫学杂志,2020,36(14):1735-1739. DOI:10.3969/j.issn.1000-484X.2020.14.015.
[15] 崔丹,冯秀莉,李志惠,等. 利奈唑胺与微卡联用对耐多药肺结核的免疫功能影响及临床疗效分析[J]. 解放军预防医学杂志,2020,38(6):61-63.
[16] 程俊伟,王杰,郁春要. 补肺养阴方联合利奈唑胺对复治肺结核患者呼吸功能、炎性因子及B、T淋巴细胞衰减子的影响[J]. 广东医学,2020,41(5):515-519. DOI:10.13820/j.cnki.gdyx.20192793.

利奈唑胺联合HRZE抗结核方案治疗肺结核的疗效及对T淋巴细胞亚群水平的影响

Linezolid combined with HRZE antituberculosis regimen in treatment of pulmonary tuberculosis and its effect T lymphocyte subsets

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

[1]	朱秀兰罗勇强邓玉玲莫丽英. 不同肺结核患者结核杆菌菌型测定及药物敏感性分析 [J]. 国际医药卫生导报, 2023, 29(8): 1140-1143.
[2]	叶毓琪朱爱勇王欣国廖小刚. 中国学生肺结核就诊延迟率的meta分析 [J]. 国际医药卫生导报, 2023, 29(6): 753-761.
[3]	江坤洪何立乾王挺伍小英蔡晓婷. 应用动态变化空间扫描技术分析2018—2021年广州市肺结核空间聚集性 [J]. 国际医药卫生导报, 2023, 29(5): 680-683.
[4]	梁志强刘国标陈琪琛杜雨华吴桂锋雷宇包婉玲李华刘志辉. 广州市越秀区2018—2022年常住人口肺结核患者治疗延误情况分析 [J]. 国际医药卫生导报, 2023, 29(10): 1333-1337.
[5]	包婉玲刘玉美梁志强刘国标陈琪琛杜雨华吴桂锋雷宇李华刘志辉. 广州市越秀区2018—2022年流动人口肺结核流行情况分析 [J]. 国际医药卫生导报, 2023, 29(10): 1338-1342.
[6]	龚兰许婉华谢贝杨瑜吴玲王楠刘志辉李华孟繁荣董海平. 肺结核患者治疗过程中血清IFN-γ表达水平变化分析 [J]. 国际医药卫生导报, 2023, 29(10): 1343-1348.